{"entity":{"id":"varsetatug-masetecan","kind":"drug","name":"Varsetatug masetecan","aka":["CX-2051","Varseta-M"],"tldr":"Varsetatug masetecan is an experimental masked antibody-drug conjugate from CytomX Therapeutics, in phase 1 trials for metastatic colorectal cancer.","summary":"Varsetatug masetecan (CX-2051, Varseta-M) is a masked antibody-drug conjugate (Probody ADC, topoisomerase-1 inhibitor payload) from CytomX Therapeutics. A masked, conditionally activated antibody-drug conjugate directed at EpCAM that carries a topoisomerase-1 inhibitor payload. Its furthest stage is phase 1, for metastatic colorectal cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1 dose expansion in colorectal cancer (NCT06265688); combination study NCT07900165 not yet recruiting. FDA Fast Track for relapsed/refractory metastatic colorectal cancer (27 August 2026). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"CytomX Therapeutics: finviz.com","url":"https://finviz.com/news/386131/cytomx-therapeutics-announces-fda-fast-track-designation-for-varsetatug-masetecan-varseta-m-for-relapsedrefractory-metastatic-colorectal-cancer-rr-mcrc"},{"label":"CytomX Therapeutics: cytomx.com","url":"https://cytomx.com/pipeline/"},{"label":"ClinicalTrials.gov: trials of CX-2051","url":"https://clinicaltrials.gov/search?intr=CX-2051"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":["epcam"],"drugs":[],"companies":["cytomx-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06265688","nct07900165"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CX-2051","modality":"Masked antibody-drug conjugate (Probody ADC, topoisomerase-1 inhibitor payload)","mechanism":"A masked, conditionally activated antibody-drug conjugate directed at EpCAM that carries a topoisomerase-1 inhibitor payload.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/varsetatug-masetecan/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"}],"target":[{"id":"epcam","kind":"target","name":"EpCAM","route":"/targets/epcam/"}],"company":[{"id":"cytomx-therapeutics","kind":"company","name":"CytomX Therapeutics","route":"/companies/cytomx-therapeutics/"}],"trial":[{"id":"nct06265688","kind":"trial","name":"First In Human Study of CX-2051 in Advanced Solid Tumors","route":"/trials/nct06265688/"},{"id":"nct07900165","kind":"trial","name":"Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer","route":"/trials/nct07900165/"}]}}